Nuntius Therapeutics
Nuntius Therapeutics develops transformative mRNA therapies targeting cancer, lung diseases, and neurodegenerative diseases, utilizing proprietary delivery technology, machine learning, and advanced nucleic acid engineering. Their innovative nanocarriers outperform existing technologies, enabling targeted treatment beyond the liver. The company is positioned to make significant advancements in genetic medicine, with a focus on patient outcomes and collaboration with industry experts.
Nuntius Therapeutics
Nuntius Therapeutics develops transformative mRNA therapies targeting cancer, lung diseases, and neurodegenerative diseases, utilizing proprietary delivery technology, machine learning, and advanced nucleic acid engineering. Their innovative nanocarriers outperform existing technologies, enabling targeted treatment beyond the liver. The company is positioned to make significant advancements in genetic medicine, with a focus on patient outcomes and collaboration with industry experts.
TL;DR
Founded: 2021
HQ / Legal presence: London, United Kingdom (company site also references a Delaware, US corporate entity)
Technology focus: mRNA therapeutics with proprietary cell-specific delivery nanocarriers, plus machine learning and nucleic-acid engineering
Founders / leadership: Benita Nagel (Co‑Founder & CEO); Albert Kwok (Co‑Founder & CSO)
Funding signal: Pre‑Seed (Mar 22, 2021) led by Y Combinator; total amount not publicly disclosed
Company Overview
Problem Domain
Genetic medicines for cancer, lung diseases, and neurodegenerative diseases.
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
Public profiles report the round involved three investors (includes BACKED VC and Eight Capital); total amount not disclosed in accessible records.
Investor Signal
“Backed by Y Combinator; other reported investors include BACKED VC and Eight Capital.”